Asymmetric dimethylarginine, endothelial dysfunction and renal disease

International Journal of Molecular Sciences

Volumn 13, Issue 9, 2012, Pages 11288-11311

  Aldámiz Echevarría, Luis ^a   Andrade, Fernando ^a  

^a HOSPITAL DE CRUCES   (Spain)

Author keywords

Arginine (Arg); Asymmetric dimethylarginine (ADMA); Children; Dimethylarginine dimethylaminohydrolase (DDAH); Endothelial dysfunction; Kidney; Methylarginines; Nitric oxide; Oxidative stress; Renal failure

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ARGININE; DIMETHYLARGININASE; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; AMIDASE; BIOLOGICAL MARKER; N,N-DIMETHYLARGININE;

ABDOMINAL CRAMP; AMINO ACID METABOLISM; CARDIOVASCULAR RISK; CONSTIPATION; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN RESTRICTION; PROTEINURIA; REVIEW; RISK ASSESSMENT; RISK FACTOR; ADULT; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; CHEMISTRY; CHILD; DISEASE COURSE; ENDOTHELIUM CELL; KIDNEY; METABOLISM; PATHOLOGY; VASCULAR ENDOTHELIUM;

ADULT; AMIDOHYDROLASES; ARGININE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHILD; DISEASE PROGRESSION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; NITRIC OXIDE; OXIDATIVE STRESS; RISK FACTORS;

EID: 84866889266     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms130911288     Document Type: Review

References (123)

1. Clarke, R.; Daly, L.; Robinson, K.; Naughten, E.; Cahalane, S.; Fowler, B.; Graham, I. Hyperhomocysteinemia: An independent risk factor for vascular disease. N. Engl. J. Med. 1991, 324, 1149-1155.
2. Aldámiz-Echevarria, L.; Sanjurjo, P.; Vallo, A.; Aquino, L.; Perez-Nanclares, G.; Gimeno, P.; Rueda, M.; Ruiz, I.; Urreizti, R.; Rodriguez-Soriano, J. Hyperhomocysteinemia in children with renal transplants. Pediatr. Nephrol. 2002, 17, 718-723.
3. Nitsch, D.D.; Ghilardi, N.; Muhl, H.; Nitsch, C.; Brune, B.; Pfeilschifter, J. Apoptosis and expression of inducible nitric oxide synthase are mutually exclusive in renal mesangial cell. Am. J. Pathol. 1997, 150, 889-900.
4. Tojo, A.; Welch, W.J.; Bremen, V.; Kimoto, M.; Kimura, K.; Omata, M.; Ogawa, T.; Vallance, P.; Wilcox, C.S. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int. 1997, 52, 1593-1601.
5. Holmqvist, B.; Olsson, C.F.; Svensson, M.L.; Svanborg, C.; Forsell, J.; Alm, P. Expression of nitric oxide synthase isoforms in the mouse kidney: Cellular localization and influence by lipopolysaccharide and Toll-like receptor 4. J. Mol. Histol. 2005, 36, 499-516.
6. Morrisey, J.J.; McCracken, R.; Kaneto, H.; Vehaskari, M.; Montani, D.; Klahr, S. Location of an inducible nitric oxide synthase mRNA in the normal kidney. Kidney Int. 1994, 45, 998-1005.
7. Raij, L.; Shultz, P.J. Endothelium-Derived relaxing factor, nitric oxide: Effects on and production by mesangial cells and glomerulus. J. Am. Soc. Nephrol. 1993, 3, 1435-1441.
8. Perticone, F.; Maio, R.; Perticone, M.; Sciacqua, A.; Shehaj, E.; Naccarato, P.; Sesti, G. Endothelial dysfunction and subsequent decline in glomerular filtration rate in hypertensive patients. Circulation 2010, 122, 379-384.
9. Crespo, M.; Campistol, J.M. Disfunción endotelial en transplante renal. Nefrología 2003, 23, 52-58.
10. Caló, L.A.; Dall'Amico, R.; Pagnin, E.; Bertipaglia, L.; Zacchello, G.; Davis, P.A. Oxidative stress and post-transplant hypertension in pediatric kidney-transplanted patients. J. Pediatr. 2006, 149, 53-57.
11. Sahin, G.; Akay, O.M.; Bal, C.; Yalcin, A.U.; Gulbas, Z. The effect of calcineurin inhibitors on endothelial and platelet function in renal transplant patients. Clin. Nephrol. 2011, 76, 218-225.
12. Trapp, A.; Weis, M. The impact of immunosuppression on endothelial function. J. Cardiovasc. Pharmacol. 2005, 45, 81-87.
13. Morris, S.T.; McMurray, J.J.V.; Rodger, R.S.; Farmer, R.; Jardine, A.G. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Kidney Int. 2000, 57, 1100-1106.
14. Schmidt, R.J.; Yokota, S.; Tracy, T.S.; Sorkin, M.I.; Baylis, C. Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis. Am. J. Physiol. 1999, 276, 794-797.
15. Loscalzo, J. L-Arginine and atherothrombosis. J. Nutr. 2004, 134, 2798S-2800S.
16. Vallance, P.; Leiper, J. Cardiovascular biology of the asymmetric dimethylarginine: Dimethylarginine dimethylaminohydrolase pathway. Arterioescler. Thromb. Vasc. Biol. 2004, 24, 1023-1030.
17. Böger, R.H.; Sydow, K.; Borlak, J.; Thum, T.; Lenzen, H.; Schubert, B.; Tsikas, D.; Bode-Boger, S.M. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: Involvement of S-adenosylmethionine-dependent methyltransferases. Circ. Res. 2000, 87, 99-105.
18. Tojo, A.; Welch, W.J.; Bremer, V.; Kimoto, M.; Kimura, K.; Omata, M.; Ogawa, T.; Vallance, P.; Wilcox, C.S. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int. 1997, 52, 1593-1601.
19. Kielstein, J.T.; Salpeter, S.R.; Bode-Boeger, S.M.; Cooke, J.P.; Fliser, D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function-A meta-analysis. Nephrol. Dial. Transpl. 2006, 21, 2446-2451.
20. Kielstein, J.T.; Zoccali, C. Asymmetric dimethylarginine: A novel marker of risk and a potential target for therapy in chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2008, 17, 609-615.
21. Kiechl, S.; Lee, T.; Santer, P.; Thompson, G.; Tsimikas, S.; Egger, G.; Holt, D.W.; Willeit, J.; Xu, Q.; Mayr, M. Asymmetric and symmetric dimethylarginines are of similar predictive value for cardiovascular risk in the general population. Atherosclerosis 2009, 205, 261-265.
22. Oner-Iyidogan, Y.; Oner, P.; Kocak, H.; Gurdol, F.; Bekpinar, S.; Unlucerci, Y.; Caliskan, Y.; Cetinalp-Demircan, P.; Kocak, T.; Turkmen, A. Dimethylarginines and inflammation markers in patients with chronic kidney disease undergoing dialysis. Clin. Exp. Med. 2009, 9, 235-241.
23. Schepers, E.; Barreto, D.V.; Liabeuf, S.; Glorieux, G.; Eloot, S.; Barreto, F.C.; Massy, Z.; Vanholder, R. European Uremic Toxin Work Group (EUTox). Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2011, 6, 2374-2383.
24. Brooks, E.R.; Langman, C.B.; Wang, S.; Price, H.E.; Hodges, A.L.; Darling, L.; Yang, A.Z.; Smith, F.A. Methylated arginine derivatives in children and adolescents with chronic kidney disease. Pediatr. Nephrol. 2009, 24, 129-134.
25. Bode-Böger, S.M.; Scalera, F.; Kielstein, J.T.; Martens-Lobenhoffer, J.; Breithardt, G.; Fobker, M.; Reinecke, H. Symmetrical dimethylarginine: A new combined parameter for renal function and extent of coronary artery disease. J. Am. Soc. Nephrol. 2006, 17, 1128-1134.
26. Schepers, E.; Glorieux, G.; Dou, L.; Cerini, C.; Gayrard, N.; Louvet, L.; Maugard, C.; Preus, P.; Rodriguez-Ortiz, M.; Argiles, A. et al. European Uremic Toxin Work Group (EUTox). Guanidino compounds as cause of cardiovascular damage in chronic kidney disease: An in vitro evaluation. Blood Purif. 2010, 30, 277-287.
27. Nijveldt, R.J.; Teerlink, T.; van Guldener, C.; Prins, H.A.; van Lambalgen, A.A.; Stehouwer, C.D.; Rauwerda, J.A.; van Leeuwen, P.A. Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia. Nephrol. Dial. Transpl. 2003, 18, 2542-2550.
28. Leiper, J.M.; Santa María, J.; Chubb, A.; MacAllister, R.J.; Charles, I.G.; Whitley, G.S.; Vallance, P. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem. J. 1999, 343, 209-214.
29. Torondel, B.; Nandi, M.; Kelly, P.; Wojciak-Stothard, B.; Fleming, I.; Leiper, J. Adenoviral-Mediated overexpression of DDAH improves vascular tone regulation. Vasc. Med. 2010, 15, 205-213.
30. Sydow, K.; Fortmann, S.P.; Fair, J.M.; Varady, A.; Hlatky, M.A.; Go, A.S.; Iribarren, C.; Tsao, P.S. ADVANCE Investigators. Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities. Clin. Chem. 2010, 56, 111-120.
31. Perticone, F.; Sciacqua, A.; Maio, R.; Perticone, M.; Galiano Leone, G.; Bruni, R.; Di Cello, S.; Pascale, A.; Talarico, G.; Greco, L. et al. Endothelial dysfunction, ADMA and insulin resistance in essential hypertension. Int. J. Cardiol. 2010, 142, 236-241.
32. Wilcken, D.E.; Sim, A.S.; Wang, J.; Wang, X.L. Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism. Mol. Genet. Metab. 2007, 91, 309-317.
33. Sibal, L.; Agarwal, S.C.; Home, P.D.; Boger, R.H. The role of asymmetric dimethylarginine (adma) in endothelial dysfunction and cardiovascular disease. Curr. Cardiol. Rev. 2010, 6, 82-90.
34. Cardounel, A.J.; Cui, H.; Samouilov, A.; Johnson, W.; Kearns, P.; Tsai, A.L.; Berka, V.; Zweier, J.L. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J. Biol. Chem. 2007, 282, 879-887.
35. Böger, R.H. Asymmetric dimethylarginine (ADMA): A novel risk marker in cardiovascular medicine and beyond. Ann. Med. 2006, 38, 126-136.
36. Bermúdez, V.; Bermúdez, F.; Acosta, G.; Acosta, A.; Añez, J.; Andara, C.; Leal, E.; Cano, C.; Manuel, V.; Hernández, R. et al. Molecular mechanisms of endothelial dysfunction: From nitric oxide synthesis to ADMA inhibition. Am. J. Ther. 2008, 15, 326-333.
37. Laakso, M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999, 48, 937-942.
38. Miyazaki, H.; Matsuoka, H.; Cooke, J.P.; Usui, M.; Ueda, S.; Okuda, S.; Imaizumi, T. Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis. J. Cardiol. 1999, 33, 105-106.
39. Stühlinger, M.C.; Abbasi, F.; Chu, J.W.; Lamendola, C.; McLaughlin, T.L.; Cooke, J.P.; Reaven, G.M.; Tsao, P.S. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA J. Am. Med. Assoc. 2002, 287, 1420-1426.
40. Tarnow, L.; Hovind, P.; Teerlink, T.; Stehouwer, C.D.; Parving, H.H. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004, 27, 765-769.
41. Andreozzi, F.; Presta, I.; Mannino, G.C.; Scarpelli, D.; Di Silvestre, S.; Di Pietro, N.; Succurro, E.; Sciacqua, A.; Pandolfi, A.; Consoli, A.; et al. A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with insulin sensitivity. PLoS One 2012, 7, e36224.
42. Goonasekera, C.D.; Rees, D.D.; Woolard, P.; Frend, A.; Shah, V.; Dillon, M.J. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J. Hypertens. 1997, 15, 901-909.
43. Ueda, S.; Yamagishi, S.; Kaida, Y.; Okuda, S. Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease. Nephrology 2007, 12, 582-590.
44. Mallamaci, F.; Zoccali, C. Clinical implications of elevated asymmetric dimethylarginine in chronic kidney disease and end-stage renal disease. J. Ren. Nutr. 2009, 19, 25-28.
45. Alsagaff, M.Y.; Thaha, M.; Aminuddin, M.; Yogiarto, R.M.; Yogiantoro, M.; Tomino, Y. Asymmetric dimethylarginine: A novel cardiovascular risk factor in end-stage renal disease. J. Int. Med. Res. 2012, 40, 340-349.
46. Stühlinger, M.C.; Tsao, P.S.; Her, J.H.; Kimoto, M.; Balint, R.F.; Cooke, J.P. Homocysteine impairs the nitric oxide synthase pathway: Role of asymmetric dimethylarginine. Circulation 2001, 104, 2569-2575.
47. Lu, T.M.; Ding, Y.A.; Leu, H.B.; Yin, W.H.; Sheu, W.H.; Chu, K.M. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am. J. Cardiol. 2004, 94, 157-161.
48. Hasanoǧlu, A.; Okur, I.; Oren, A.C.; Biberoǧlu, G.; Oktar, S.; Eminoǧlu, F.T.; Tümer, L. The levels of asymmetric dimethylarginine, homocysteine and carotid intima-media thickness in hypercholesterolemic children. Turk. J. Pediatr. 2011, 53, 522-527.
49. Zhang, W.Z.; Venardos, K.; Chin-Dusting, J.; Kaye, D.M. Adverse effects of cigarette smoke on NO bioavailability: Role of arginine metabolism and oxidative stress. Hypertension 2006, 48, 278-485.
50. Napora, M.; Graczykowska, A.; Próchniewska, K.; Zdrojewski, Z.; Całka, A.; Górny, J.; Stompór, T. Relationship between serum asymmetric dimethylarginine and left ventricular structure and function in patients with end-stage renal disease treated with hemodialysis. Pol. Arch. Med. Wewn. 2012, 122, 226-234.
51. Zoccali, C.; Mallamaci, F.; Maas, R.; Benedetto, F.A.; Tripepi, G.; Malatino, L.S.; Cataliotti, A.; Bellanuova, I.; Böger, R. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 2002, 62, 339-345.
52. Shi, B.; Ni, Z.; Zhou, W.; Yu, Z.; Gu, L.; Mou, S.; Fang, W.; Wang, Q.; Cao, L.; Yan, Y. et al. Circulating levels of asymmetric dimethylarginine are an independent risk factor for left ventricular hypertrophy and predict cardiovascular events in pre-dialysis patients with chronic kidney disease. Eur. J. Intern. Med. 2010, 21, 444-448.
53. Chen, Y.; Li, Y.; Zhang, P.; Traverse, J.H.; Hou, M.; Xu, X.; Kimoto, M.; Bache, R.J. Dimethylarginine dimethylaminohydrolase and endothelial dysfunction in failing hearts. Am. J. Physiol. Heart. Circ. Physiol. 2005, 289, 2212-2219.
54. Notsu, Y.; Nabika, T.; Bokura, H.; Suyama, Y.; Kobayashi, S.; Yamaguchi, S.; Masuda, J. Evaluation of asymmetric dimethylarginine and homocysteine in microangiopathy-related cerebral damage. Am. J. Hypertens. 2009, 22, 257-262.
55. Lang, D.; Kredan, M.B.; Moat, S.J.; Hussain, S.A.; Powell, C.A.; Bellamy, M.F.; Powers, H.J.; Lewis, M.J. Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: Role for superoxide anions. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 422-427.
56. Dayal, S.; Rodionov, R.N.; Arning, E.; Bottiglieri, T.; Kimoto, M.; Murry, D.J.; Cooke, J.P.; Faraci, F.M.; Lentz, S.R. Tissue-Specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia. Am. J. Physiol. Heart Circ. Physiol. 2008, 295, 816-825.
57. Van Guldener, C.; Nanayakkara, P.W.; Stehouwer, C.D.A. Homocysteine and asymmetric dimethylarginine (ADMA): Biochemically linked but differently related to vascular disease in chronic kidney disease. Clin. Chem. Lab. Med. 2007, 45, 1683-1687.
58. Young, J.M.; Terrin, N.; Wang, X.; Greene, T.; Beck, G.J.; Kusek, J.W.; Collins, A.J.; Sarnak, M.J.; Menon, V. Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009, 4, 1115-1120.
59. Ito, A.; Tsao, P.S.; Adimoolam, S.; Kimoto, M.; Ogawa, T.; Cooke, J.P. Novel mechanism for endothelial dysfunction: Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999, 99, 3092-3095.
60. Feng, M.; Liu, L.; Guo, Z.; Xiong, Y. Gene transfer of dimethylarginine dimethylaminohydrolase-2 improves the impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells induced by lysophosphatidylcholine. Eur. J. Pharmacol. 2008, 584, 49-56.
61. Rocha, M.S.; Teerlink, T.; Janssen, M.C.; Kluijtmans, L.A.; Smulders, Y.; Jakobs, C.; Tavares de Almeida, I.; Rivera, I.; Castro, R.; Blom, H.J. Asymmetric dimethylarginine in adults with cystathionine β-synthase deficiency. Atherosclerosis 2012, 222, 509-511.
62. Schnabel, R.; Blankenberg, S.; Lubos, E.; Lackner, K.J.; Rupprecht, H.J.; Espinola-Klein, C.; Jachmann, N.; Post, F.; Peetz, D.; Bickel, C. et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: Results from the AtheroGene Study. Circ. Res. 2005, 97, 53-59.
63. Kielstein, J.T.; Böger, R.H.; Bode-Böger, S.M.; Frölich, J.C.; Haller, H.; Ritz, E.; Fliser, D. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J. Am. Soc. Nephrol. 2002, 13, 170-176.
64. Kielstein, J.T.; Böger, R.H.; Bode-Böger, S.M.; Schäffer, J.; Barbey, M.; Koch, K.M.; Frölich, J.C. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease. J. Am. Soc. Nephrol. 1999, 10, 594-600.
65. Jacobi, J.; Tsao, P.S. Asymmetrical dimethylarginine in renal disease: Limits of variation or variation limits? A systematic review. Am. J. Nephrol. 2008, 28, 224-237.
66. Tripepi, G.; Mattace Raso, F.; Sijbrands, E.; Seck, M.S.; Maas, R.; Boger, R.; Witteman, J.; Rapisarda, F.; Malatino, L.; Mallamaci, F. et al. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clin. J. Am. Soc. Nephrol. 2011, 6, 1714-1721.
67. Dobrian, A.D. ADMA and NOS regulation in chronic renal disease: Beyond the old rivalry for L-arginine. Kidney Int. 2012, 81, 722-724.
68. Kajimoto, H.; Kai, H.; Aoki, H.; Yasuoka, S.; Anegawa, T.; Aoki, Y.; Ueda, S.; Okuda, S.; Imaizumi, T. Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: New effect of asymmetric dimethylarginine. Kidney Int. 2012, 81, 762-768.
69. Zoccali, C.; Kielstein, J.T. Asymmetric dimethylarginine: A new player in the pathogenesis of renal disease? Curr. Opin. Nephrol. Hypertens. 2006, 15, 314-320.
70. Kielstein, J.T.; Martens-Lobenhoffer, J.; Vollmer, S.; Bode-Böger, S.M. L-Arginine, ADMA, SDMA, creatinine, MDRD formula: Detour to renal function testing. J. Nephrol. 2008, 21, 959-961.
71. Chen, G.F.; Moningka, N.C.; Sasser, J.M.; Zharikov, S.; Cunningham, M., Jr.; Tain, Y.L.; Schwartz, I.F.; Baylis, C. Arginine and asymmetric dimethylarginine in puromycin aminonucleoside-induced chronic kidney disease in the rat. Am. J. Nephrol. 2012, 35, 40-48.
72. Busch, M.; Fleck, C.; Wolf, G.; Stein, G. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease-Possible candidates for paradoxical epidemiology? Amino Acids 2006, 30, 225-232.
73. Muscheites, J.; Meyer, A.A.; Drueckler, E.; Wigger, M.; Fischer, D.C.; Kundt, G.; Kienast, W.; Haffner, D. Assessment of the cardiovascular system in pediatric chronic kidney disease: A pilot study. Pediatr. Nephrol. 2008, 23, 2233-2239.
74. Lu, T.M.; Chung, M.Y.; Lin, C.C.; Hsu, C.P.; Lin, S.J. Asymmetric dimethylarginine and clinical outcomes in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2011, 6, 1566-1572.
75. Marescau, B.; Nagels, G.; Possemiers, I.; de Broe, M.E.; Because, I.; Billiouw, J.M.; Lornoy, W.; de Deyn, P.P. Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency. Metabolism 1997, 46, 1024-1031.
76. Pi, J.; Kumagai, Y.; Sun, G.; Shimojo, N. Improved method for simultaneous determination of L-arginine and its mono- and dimethylated metabolites in biological samples by high-performance liquid chromatography. J. Chromatogr. B 2000, 742, 199-203.
77. Tsikas, D.; Schubert, B.; Gutzki, F.M.; Sandmann, J.; Frölich, J.C. Quantitative determination of circulating and urinary asymmetric dimethylarginine (ADMA) in humans by gas chromatography-tandem mass spectrometry as methyl ester tri(N-pentafluoropropionyl) derivative. J. Chromatogr. B 2003, 798, 87-99.
78. Martens-Lobenhoffer, J.; Krug, O.; Bode-Böger, S.M. Determination of arginine and asymmetric dimethylarginine (ADMA) in human plasma by liquid chromatography/mass spectrometry with the isotope dilution technique. J. Mass. Spectrom. 2004, 39, 1287-1294.
79. Schwedhelm, E.; Tan-Andresen, J.; Maas, R.; Riederer, U.; Schulze, F.; Böger, R.H. Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin. Chem. 2005, 51, 1268-1271.
80. Martens-Lobenhoffer, J.; Krug, O.; Bode-Böger, S.M. Fast and efficient determination of arginine, symmetric dimethylarginine, and asymmetric dimethylarginine in biological fluids by hydrophilic-Interaction liquid chromatography-electrospray tandem mass spectrometry. Clin. Chem. 2006, 52, 488-493.
81. Wilcken, D.E.; Wang, J.; Sim, A.S.; Green, K.; Wilcken, B. Asymmetric dimethylarginine in homocystinuria due to cystathionine beta-synthase deficiency: Relevance of renal function. J. Inherit. Metab. Dis. 2006, 29, 30-37.
82. Bishop, M.J.; Crow, B.; Norton, D.; Paliakov, E.; George, J.; Bralley, J.A. Direct analysis of un-derivatized asymmetric dimethylarginine (ADMA) and L-arginine from plasma using mixed-mode ion-exchange liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 2007, 859, 164-169.
83. Schwedhelm, E.; Maas, R.; Tan-Andresen, J.; Schulze, F.; Riederer, U.; Böger, R.H. High-Throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J. Chromatogr. B 2007, 851, 211-219.
84. Weaving, G.; Rocks, B.F.; Bailey, M.P.; Titheradge, M.A. Arginine and methylated arginines in human plasma and urine measured by tandem mass spectrometry without the need for chromatography or sample derivatisation. J. Chromatogr. B 2008, 874, 27-32.
85. Zhang, W.; Zhou, C.; Xie, J.; Chen, B.; Chang, L. Serum asymmetric dimethylarginine and endothelial function after renal transplantation. J. Cent. South Univ. (Med. Sci.) 2009, 34, 289-294.
86. El-Khoury, J.M.; Bunch, D.R.; Reineks, E.; Jackson, R.; Steinle, R.; Wang, S. A simple and fast liquid chromatography-tandem mass spectrometry method for measurement of underivatized L-arginine, symmetric dimethylarginine, and asymmetric dimethylarginine and establishment of the reference ranges. Anal. Bioanal. Chem. 2012, 402, 771-779.
87. Tain, Y.L.; Huang, L.T. Asymmetric dimethylarginine: Clinical applications in pediatric medicine. J. Formos. Med. Assoc. 2011, 110, 70-77.
88. Wang, S.; Vicente, F.B.; Miller, A.; Brooks, E.R.; Price, H.E.; Smith, F.A. Measurement of arginine derivatives in pediatric patients with chronic kidney disease using high-performance liquid chromatography-tandem mass spectrometry. Clin. Chem. Lab. Med. 2007, 45, 1305-1312.
89. Jehlička, P.; Stožický, F.; Mayer, O., Jr.; Varvařovská, J.; Racek, J.; Trefil, L.; Siala, K. Asymmetric dimethylarginine and the effect of folate substitution in children with familial hypercholesterolemia and diabetes mellitus type 1. Physiol. Res. 2009, 58, 179-184.
90. Heilman, K.; Zilmer, M.; Zilmer, K.; Kool, P.; Tillmann, V. Elevated plasma adiponectin and decreased plasma homocysteine and asymmetric dimethylarginine in children with type 1 diabetes. Scand. J. Clin. Lab. Invest. 2009, 69, 85-91.
91. Huemer, M.; Simma, B.; Mayr, D.; Möslinger, D.; Mühl, A.; Schmid, I.; Ulmer, H.; Bodamer, O.A. Free asymmetric dimethylarginine (ADMA) is low in children and adolescents with classical phenylketonuria (PKU). J. Inherit. Metab. Dis. 2012, in press.
92. Andrade, F.; Rodríguez-Soriano, J.; Prieto, J.A.; Aguirre, M.; Ariceta, G.; Lage, S.; Azcona, I.; Prado, C.; Sanjurjo, P.; Aldámiz-Echevarría, L. Methylation cycle, arginine-creatine pathway and asymmetric dimethylarginine in paediatric renal transplant. Nephrol. Dial. Transpl. 2011, 26, 328-336.
93. Arcos, M.I.; Fujihara, C.K.; Sesso, A.; de Almeida Prado, E.B.; de Almeida Prado, M.J.; de Nucci, G.; Zatz, R. Mechanisms of albuminuria in the chronic nitric oxide inhibition model. Am. J. Physiol. Renal. Physiol. 2000, 279, 1060-1066.
94. Okubo, K.; Hayashi, K.; Wakino, S.; Matsuda, H.; Kubota, E.; Honda, M.; Tokuyama, H.; Yamamoto, T.; Kajiya, F.; Saruta, T. Role of asymmetrical dimethylarginine in renal microvascular endothelial dysfunction in chronic renal failure with hypertension. Hypertens. Res. 2005, 28, 181-189.
95. Kaida, Y.; Ueda, S.; Yamagishi, S.I.; Nakayama, Y.; Ando, R.; Iwatani, R.; Fukami, K.; Okuda, S. Proteinuria elevates asymmetric dimethylarginine levels via protein arginine methyltransferase-1 overexpression in a rat model of nephrotic syndrome. Life Sci. 2012, in press.
96. Caglar, K.; Yilmaz, M.I.; Sonmez, A.; Cakir, E.; Kaya, A.; Acikel, C.; Eyileten, T.; Yenicesu, M.; Oguz, Y.; Bilgi, C. et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int. 2006, 70, 781-787.
97. Matsumoto, Y.; Ueda, S.; Yamagishi, S.; Matsuguma, K.; Shibata, R.; Fukami, K.; Matsuoka, H.; Imaizumi, T.; Okuda, S. Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J. Am. Soc. Nephrol. 2007, 18, 1525-1533.
98. Yilmaz, M.I.; Saglam, M.; Caglar, K.; Cakir, E.; Ozgurtas, T.; Sonmez, A.; Eyileten, T.; Yenicesu, M.; Acikel, C.; Oguz, Y.; et al. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. Transplantation 2005, 80, 1660-1666.
99. Zoccali, C. Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease. Blood Purif. 2002, 20, 469.
100. Teplan, V.; Schück, O.; Racek, J.; Siroka, R.; Haluzik, M.; Kudla, M.; Vitko, S. Asymmetric dimethylarginine and adiponectin after renal transplantation: Role of obesity. J. Ren. Nutr. 2008, 18, 154-157.
101. Teplan, V.; Malý, J.; Gürlich, R.; Teplan, V., Jr.; Kudla, M.; Pit'ha, J.; Racek, J.; Haluzík, M.; Senolt, L.; Stollová, M. Muscle and fat metabolism in obesity after kidney transplantation: No effect of peritoneal dialysis or hemodialysis. J. Ren. Nutr. 2012, 22, 166-170.
102. Abedini, S.; Meinitzer, A.; Holme, I.; März, W.; Weihrauch, G.; Fellstrøm, B.; Jardine, A.; Holdaas, H. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney Int. 2010, 77, 44-50.
103. Zhang, D.L.; Liu, J.; Liu, S.; Zhang, Y.; Liu, W.H. The differences of asymmetric dimethylarginine removal by different dialysis treatments. Ren. Fail. 2010, 32, 935-940.
104. Maas, R. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA). Vasc. Med. 2005, 10, S49-S57.
105. Goralczyk, T.; Tisonczyk, J.; Fijorek, K.; Undas, A. High tea and vegetable consumption is associated with low ADMA generation in older healthy subjects. Metabolism 2012, 61, 1171-1176.
106. Saran, R.; Novak, J.E.; Desai, A.; Abdulhayoglu, E.; Warren, J.S.; Bustami, R.; Handelman, G.J.; Barbato, D.; Weitzel, W.; D'Alecy, L.G. et al. Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): A pilot study. Nephrol. Dial. Transpl. 2003, 18, 2415-2420.
107. Nanayakkara, P.W.; Kiefte-de Jong, J.C.; ter Wee, P.M.; Stehouwer, C.D.; van Ittersum, F.J.; Olthof, M.R.; Teerlink, T.; Twisk, J.W.; van Guldener, C.; Smulders, Y.M. Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD. Am. J. Kidney Dis. 2009, 53, 41-50.
108. Teplan, V.; Schück, O.; Racek, J.; Mareckova, O.; Stollova, M.; Hanzal, V.; Malý, J. Reduction of plasma asymmetric dimethylarginine in obese patients with chronic kidney disease after three years of a low-protein diet supplemented with keto-amino acids: A randomized controlled trial. Wien. Klin. Wochenschr. 2008, 120, 478-485.
109. Cupiste, A.; Ghiadoni, L.; D'Alessandro, C.; Cardas, I.; Morelli, E.; Panichi, V.; Locati, D.; Morandi, S.; Saba, A.; Barsotti, G.; et al. Soy protein diet improves endothelial dysfunction in renal transplant patients. Nephrol. Dial. Transpl. 2007, 22, 229-234.
110. Urquhart, B.L.; House, A.A. Assessing plasma total homocysteine in patients with end-stage renal disease. Perit. Dial. Int. 2007, 27, 476-488.
111. Thaha, M.; Widodo, P.W.; Yogiantoro, M.; Tomino, Y. Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients. Clin. Nephrol. 2008, 69, 24-32.
112. Ruiz, M.C.; Moreno, J.M.; Ruiz, N.; Vargas, F.; Asensio, C.; Osuna, A. Effect of statin treatment on oxidative stress and renal function in renal transplantation. Transpl. Proc. 2006, 38, 2431-2433.
113. Trimarchi, H.M.; Brennan, S.; González, J.M.; Suki, W.N. Effects of the statins in kidney transplantation. Medicina (B. Aires) 2000, 60, 457-465.
114. Panichi, V.; Mantuano, E.; Paoletti, S.; Santi, S.; Manca Rizza, G.; Cutrupi, S.; Pizzini, P.; Spoto, B.; Tripepi, G.; Zoccali, C. Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. J. Nephrol. 2008, 21, 38-44.
115. Lim, A.; Manley, K.J.; Roberts, M.A.; Fraenkel, M.B. Fish oil treatment for kidney transplant recipients: A meta-analysis of randomized controlled trials. Transplantation 2007, 83, 831-838.
116. Beavers, K.M.; Beavers, D.P.; Bowden, R.G.; Wilson, R.L.; Gentile, M. Omega-3 fatty acid supplementation and total homocysteine levels in end-stage renal disease patients. Nephrology (Carlton) 2008, 13, 284-288.
117. Małyszko, J.; Małyszko, J.S.; Brzósko, S.; Pawlak, K.; Myśliwiec, M. Effects of fluvastatin on homocysteine and serum lipids in kidney allograft recipients. Ann. Transpl. 2002, 7, 52-54.
118. Vos, I.H.; Rabelink, T.J.; Dorland, B.; Loos, R.; van Middelaar, B.; Grone, H.J.; Joles, J.A. L-Arginine supplementation improves function and reduces inflamation in renal allografts. J. Am. Soc. Nephrol. 2001, 12, 361-367.
119. Baylis, C. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat. Clin. Pract. Nephrol. 2006, 2, 209220.
120. El-Mesallamy, H.O.; Abdel Hamid, S.G.; Gad, M.Z. Oxidative stress and asymmetric dimethylarginine are associated with cardiovascular complications in hemodialysis patients: Improvements by L-arginine intake. Kidney Blood Press. Res. 2008, 31, 189-195.
121. Bodamer, O.A.; Sahoo, T.; Beaudet, A.L.; O'Brien, W.E.; Bottiglieri, T.; Stockler-Ipsiroglu, S.; Wagner, C.; Scaglia, F. Creatine metabolism in combined methylmalonic aciduria and homocystinuria. Ann. Neurol. 2005, 57, 557-560.
122. Schramm, L.; La, M.; Heidbreder, E.; Hecker, M.; Beckman, J.S.; Lopau, K.; Zimmermann, J.; Rendl, J.; Reiners, C.; Winderl, S. et al. L-Arginine deficiency and supplementation in experimental acute renal failure and in human kidney transplantation. Kidney Int. 2002, 61, 1423-1432.
123. Schwedhelm, E.; Maas, R.; Freese, R.; Jung, D.; Lukacs, Z.; Jambrecina, A.; Spickler, W.; Schulze, F.; Böger, R.H. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: Impact on nitric oxide metabolism. Br. J. Clin. Pharmacol. 2008, 65, 51-59.